X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs JUBILANT LIFE SCIENCES - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA JUBILANT LIFE SCIENCES ABBOTT INDIA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 39.4 17.6 224.3% View Chart
P/BV x 10.1 4.6 219.2% View Chart
Dividend Yield % 0.7 0.4 173.1%  

Financials

 ABBOTT INDIA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
JUBILANT LIFE SCIENCES
Mar-14
ABBOTT INDIA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs6,110187 3,270.9%   
Low Rs3,99665 6,138.2%   
Sales per share (Unadj.) Rs1,552.2364.3 426.0%  
Earnings per share (Unadj.) Rs188.86.8 2,758.0%  
Cash flow per share (Unadj.) Rs196.424.5 801.8%  
Dividends per share (Unadj.) Rs55.003.00 1,833.3%  
Dividend yield (eoy) %1.12.4 45.7%  
Book value per share (Unadj.) Rs796.6164.9 483.1%  
Shares outstanding (eoy) m21.25159.28 13.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.3 941.7%   
Avg P/E ratio x26.818.4 145.5%  
P/CF ratio (eoy) x25.75.1 500.4%  
Price / Book Value ratio x6.30.8 830.5%  
Dividend payout %29.143.8 66.5%   
Avg Mkt Cap Rs m107,37620,061 535.2%   
No. of employees `0003.36.2 53.7%   
Total wages/salary Rs m3,93711,052 35.6%   
Avg. sales/employee Rs Th9,929.39,383.0 105.8%   
Avg. wages/employee Rs Th1,185.11,786.9 66.3%   
Avg. net profit/employee Rs Th1,207.7176.3 685.1%   
INCOME DATA
Net Sales Rs m32,98558,034 56.8%  
Other income Rs m1,170191 613.8%   
Total revenues Rs m34,15558,224 58.7%   
Gross profit Rs m5,2455,786 90.6%  
Depreciation Rs m1622,812 5.8%   
Interest Rs m383,237 1.2%   
Profit before tax Rs m6,215-72 -8,619.7%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m2,203696 316.3%   
Profit after tax Rs m4,0121,090 367.9%  
Gross profit margin %15.910.0 159.5%  
Effective tax rate %35.4-965.9 -3.7%   
Net profit margin %12.21.9 647.4%  
BALANCE SHEET DATA
Current assets Rs m22,65529,280 77.4%   
Current liabilities Rs m6,68138,912 17.2%   
Net working cap to sales %48.4-16.6 -291.8%  
Current ratio x3.40.8 450.6%  
Inventory Days Days6584 76.8%  
Debtors Days Days2951 57.5%  
Net fixed assets Rs m83555,712 1.5%   
Share capital Rs m213155 137.5%   
"Free" reserves Rs m16,71520,968 79.7%   
Net worth Rs m16,92826,265 64.4%   
Long term debt Rs m017,169 0.0%   
Total assets Rs m24,16288,606 27.3%  
Interest coverage x163.71.0 16,742.0%   
Debt to equity ratio x00.7 0.0%  
Sales to assets ratio x1.40.7 208.4%   
Return on assets %16.84.9 343.2%  
Return on equity %23.74.2 570.9%  
Return on capital %36.911.6 319.4%  
Exports to sales %037.8 0.0%   
Imports to sales %016.5 0.0%   
Exports (fob) Rs mNA21,933 0.0%   
Imports (cif) Rs mNA9,567 0.0%   
Fx inflow Rs m36922,004 1.7%   
Fx outflow Rs m3,80711,749 32.4%   
Net fx Rs m-3,43810,255 -33.5%   
CASH FLOW
From Operations Rs m1,5278,026 19.0%  
From Investments Rs m-2,148-1,744 123.2%  
From Financial Activity Rs m-1,024-4,447 23.0%  
Net Cashflow Rs m-1,6461,834 -89.7%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 75.0 3.5 2,142.9%  
Indian inst/Mut Fund % 7.9 8.7 90.8%  
FIIs % 0.1 21.2 0.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 21.1 81.0%  
Shareholders   18,270 23,815 76.7%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   SUVEN LIFE  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

DIVIS LABORATORIES share price has hit an all time high at Rs 1,409 (up 1.5%). The BSE HEALTHCARE Index is up by 1.3%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.5%) and ABBOTT INDIA (up 0.7%). The top losers include ALEMBIC PHARMA (down 0.1%) and ERIS LIFESCIENCES LIMITED (down 0.1%).

BIOCON LTD at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

BIOCON LTD share price has hit an all time high at Rs 710 (up 1.1%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 1.1%) and ABBOTT INDIA (up 0.3%). The top losers include PFIZER (down 0.1%) and FDC LTD. (down 0.6%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 26, 2018 09:51 AM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - AJANTA PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS